CMF (химиотерапия): различия между версиями
Перейти к навигации
Перейти к поиску
| [отпатрулированная версия] | [отпатрулированная версия] |
Содержимое удалено Содержимое добавлено
Нет описания правки |
|||
| Строка 1: | Строка 1: | ||
'''Cyclophosphamide Methotrexate Fluorouracil (CMF)''' is a commonly used [[Chemotherapy regimens|regimen]] of [[breast cancer chemotherapy]] that combines three anti-cancer agents: [[cyclophosphamide]], [[methotrexate]], and [[Fluorouracil|5-fluorouracil]] (5-FU).<ref name="pmid18306034">{{cite journal |author=Kimmick GG, Cirrincione C, Duggan DB, ''et al.'' |title=Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944) |journal=[[Breast Cancer Res. Treat.]] |volume= 113|issue= 3|pages= 479–90|year=2008 |pmid=18306034 |doi=10.1007/s10549-008-9943-2}}</ref> |
|||
#REDIRECT [[Режимы химиотерапии]] |
|||
While it is no longer considered most efficient all-around chemotherapy it retains a great importance in the treatment of elderly patients with luminal cancers and may become important for the treatment of [[estrogen receptor]] negative [[androgen receptor]] positive luminal ([[GATA3]] expressing) breast cancer. |
|||
The regimen was designed in order to mimic the highly successful regimen developed to treat [[Hodgkin's lymphoma]].<ref name="classic">{{cite journal |author= Ferreira Filho AF, Di Leo A, Paesmans M ''et al.'' |title= The feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and cumulative doses across institutions |journal=Annals of Oncology |volume= 13 |issue= 3|pages= 416–421|year=2002 |url=http://annonc.oxfordjournals.org/cgi/content/full/13/3/416 |pmid= 11996473 |doi= 10.1093/annonc/mdf051}}</ref> |
|||
== Метод лечения == |
|||
The treatment is administrated over a four-week cycle. On days 1 and 8 methotrexate and 5-FU are given as injections. Cyclophosphamide may be also administered intravenously in conjunction with these drugs, or may be taken as an oral tablet, taken once each day for the first 14 days of each cycle.<ref name=breakthrough>{{cite web |
|||
| url = http://www.breakthrough.org.uk/about_breast_cancer/treatment/drug_therapy/chemotherapy/cmf.html |
|||
| title = CMF (cyclophosphamide, methotrexate and 5-fluorouracil) |
|||
| accessdate = 2008-10-13 |
|||
| publisher = Breakthrough Breast Cancer |
|||
| location = UK}} Bad URL : Page and Topic not on website Dec 2012</ref> |
|||
== Побочные эффекты == |
|||
Side effects of CMF treatment include:<ref name=breakthrough/> |
|||
* [[Nausea]] |
|||
* [[Fatigue (medical)|Tiredness]] |
|||
* [[Mouth ulcer]]s |
|||
* [[Infection]]s |
|||
* [[Diarrhea]] |
|||
* [[Alopecia|Hair loss]] |
|||
* [[Female infertility|Loss of fertility]] |
|||
== Ссылки == |
|||
{{примечания}} |
|||
[[Категория:Режимы химиотерапии при раке молочной железы]] |
|||
Версия от 11:07, 18 сентября 2014
Cyclophosphamide Methotrexate Fluorouracil (CMF) is a commonly used regimen of breast cancer chemotherapy that combines three anti-cancer agents: cyclophosphamide, methotrexate, and 5-fluorouracil (5-FU).[1]
While it is no longer considered most efficient all-around chemotherapy it retains a great importance in the treatment of elderly patients with luminal cancers and may become important for the treatment of estrogen receptor negative androgen receptor positive luminal (GATA3 expressing) breast cancer.
The regimen was designed in order to mimic the highly successful regimen developed to treat Hodgkin's lymphoma.[2]
Метод лечения
The treatment is administrated over a four-week cycle. On days 1 and 8 methotrexate and 5-FU are given as injections. Cyclophosphamide may be also administered intravenously in conjunction with these drugs, or may be taken as an oral tablet, taken once each day for the first 14 days of each cycle.[3]
Побочные эффекты
Side effects of CMF treatment include:[3]
Ссылки
- ↑ Kimmick GG, Cirrincione C, Duggan DB; et al. (2008). "Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944)". Breast Cancer Res. Treat. 113 (3): 479—90. doi:10.1007/s10549-008-9943-2. PMID 18306034.
{{cite journal}}: Явное указание et al. в:|author=(справка)Википедия:Обслуживание CS1 (множественные имена: authors list) (ссылка) - ↑ Ferreira Filho AF, Di Leo A, Paesmans M; et al. (2002). "The feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and cumulative doses across institutions". Annals of Oncology. 13 (3): 416—421. doi:10.1093/annonc/mdf051. PMID 11996473.
{{cite journal}}: Явное указание et al. в:|author=(справка)Википедия:Обслуживание CS1 (множественные имена: authors list) (ссылка) - ↑ 1 2 CMF (cyclophosphamide, methotrexate and 5-fluorouracil). UK: Breakthrough Breast Cancer. Дата обращения: 13 октября 2008. Bad URL : Page and Topic not on website Dec 2012